Pharmacological Characterization of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103), a Novel Selective 5-Lipoxygenase-Activating Protein Inhibitor That Reduces Acute and Chronic Inflammation

Published 2009 View Full Article

Authors

Keywords

Journal

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Volume 331, Issue 3, Pages 1042-1050

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Online

2009-09-12

DOI

10.1124/jpet.109.158089

Ask authors/readers for more resources

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Discover Peeref hubs

Ask a Question. Answer a Question.